SAN DIEGO, CA / ACCESSWIRE / February 8, 2024 / Johnson Fistel, LLP is investigating 10x Genomics, Inc. (NASDAQ:TXG) ("10x Genomics" or the "Company") for potential securities law violations. Shareholders who have incurred losses on their investment in the company are encouraged to contact the firm to learn about potentially recovering their losses. For more details on the investigation, visit https://www.johnsonfistel.com/investigations/10x-genomics
The investigation pertains to whether executives at the company misrepresented or failed to timely disclose material and adverse information to investors.
What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or jimb@johnsonfistel.com.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, LLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Contact:
Johnson Fistel, LLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471
jimb@johnsonfistel.com or fjohnson@johnsonfistel.com
SOURCE: Johnson Fistel, LLP
View the original
press release on accesswire.com
